Showing results (481-490 of 554) with videos related to
Sort By:
Pageof 56
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 15, 2009
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter studyDaniel Y C Heng, Wanling Xie, Meredith M Regan, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2004
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinomaDavid F McDermott, Meredith M Regan, Joseph I Clark, et al.Cancers|June 27, 2024
Clinical Outcomes of Immune Checkpoint Inhibitors in Unique Cohorts Underrepresented in Clinical TrialsNeil J Shah, Alexandra Della Pia, Tianmin Wu, et al.Cancer|August 18, 2016
The efficacy of anti-PD-1 agents in acral and mucosal melanomaAlexander N Shoushtari, Rodrigo R Munhoz, Deborah Kuk, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2007
Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge ConferenceMichael B Atkins, Marc S Ernstoff, Robert A Figlin, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 22, 2007
Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanomaMalcolm S Mitchell, Judith Abrams, John A Thompson, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2009
Final version of 2009 AJCC melanoma staging and classificationCharles M Balch, Jeffrey E Gershenwald, Seng-Jaw Soong, et al.Molecular Cancer Therapeutics|October 17, 2014
Clinical utility of a blood-based BRAF(V600E) mutation assay in melanomaDavid J Panka, Elizabeth Buchbinder, Anita Giobbie-Hurder, et al.The New England Journal of Medicine|August 23, 2018
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the BrainHussein A Tawbi, Peter A Forsyth, Alain Algazi, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 11, 2021
Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 TrialMeredith M Regan, Opeyemi A Jegede, Charlene M Mantia, et al.Pageof 56